The International Myeloma Foundation Applauds FDA Approval of THALOMID ...
NORTH HOLLYWOOD, CA -- (MARKET WIRE) -- May 25, 2006 -- The International ... including VELCADE® and REVLIMID®, myeloma patients rely on multiple regimens ...
myeloma - Revlimid® Active in Relapsed Non-Hodgkin’s Lymphoma
cancer, multiple ... Post details: Revlimid® Active in Relapsed Non-Hodgkinâ ... Categories: myeloma, 31 words. Revlimid® Active in Relapsed Non-Hodgkinâ ...
Oncology - FDA Grants REVLIMID® NDA Approval
Celgene Corporation (NASDAQ: CELG) announced that the FDA granted approval of REVLIMID (lenalidomide) which is indicated for the treatment of patients with ...
BioSpace offers Pharmaceutical, Biotechnology and Healthcare industry ...
... Says Life-Changing Benefits Of REVLIMID® Recognized By The Prestigious Prix ... Sárl (CELG) Release: Updated REVLIMID® Data Presented in Newly Diagnosed ...
myeloma - June 2008, 02
cancer, multiple myeloma, myeloma cancer ... 09:16:48 pm, Categories: myeloma, 7 words. Updated REVLIMID® Results Presented In Relapsed/Refractory ...
Revlimid, Lenalidomide, CC-5013 - Chemotherapy Drugs, Chemo Drug Side ...
Revlimid is a trade name for the generic chemotherapy drug Lenalidomide. Revlimid is classified as an immunomodulatory agent and an antiangiogenic agent. Revlimid is used to treat ...
